- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Angela Moskow, Sanofi-Aventis
S
Angela Moskow
VP, Diabetes Marketing, Sanofi-Aventis
LOYAL CITIZEN: Always worked for (different iterations of) the same company
CAREER FOCUS: Diabetes
Om her most memorable moment.:
I still remember at the Lantus launch meeting, standing on the stage and issuing the challenge to the sales force to revolutionize the treatment of diabetes. When we launched Lantus in 2001, the peak forecast was $750 million, and we were pretty much told that we would never go beyond that. So when we hit $1 billion on the brand, we really celebrated. Now, in 2008, we're looking at moving toward $2 billion. And we know that there are still so many more people out there that we need to help.
Angela Moskow
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
